UY26873A1 - Complejos que contienen perfluoralquilo con radicales polares, método para su obtención y uso de los mismos. - Google Patents

Complejos que contienen perfluoralquilo con radicales polares, método para su obtención y uso de los mismos.

Info

Publication number
UY26873A1
UY26873A1 UY26873A UY26873A UY26873A1 UY 26873 A1 UY26873 A1 UY 26873A1 UY 26873 A UY26873 A UY 26873A UY 26873 A UY26873 A UY 26873A UY 26873 A1 UY26873 A1 UY 26873A1
Authority
UY
Uruguay
Prior art keywords
complexes containing
perfluoralquilo
themselves
obtaining
polar radicals
Prior art date
Application number
UY26873A
Other languages
English (en)
Inventor
Johannes Platzek
Peter Mareski
Ulrich Niedballa
Bernd Raduchel
Hanns Joachim Weinmann
Bernd Misselwitz
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of UY26873A1 publication Critical patent/UY26873A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F19/00—Metal compounds according to more than one of main groups C07F1/00 - C07F17/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Complejos que contienen perfluoralquilo con radicales polares de la fórmula general I donde R significa el radical polar, Rf es una cadena de carbono perfluorada, K es un complejo metálico y Z es grupos de enlace, apropiados para la linfografía intravenosa, el diagnóstico de tumores y para estudios de diagnóstico por imágenes del infarto y la necrosis.
UY26873A 2000-08-11 2001-08-07 Complejos que contienen perfluoralquilo con radicales polares, método para su obtención y uso de los mismos. UY26873A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10040858A DE10040858C2 (de) 2000-08-11 2000-08-11 Perfluoralkylhaltige Komplexe mit polaren Resten, Verfahren zu deren Herstellung und ihre Verwendung

Publications (1)

Publication Number Publication Date
UY26873A1 true UY26873A1 (es) 2002-03-22

Family

ID=7653176

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26873A UY26873A1 (es) 2000-08-11 2001-08-07 Complejos que contienen perfluoralquilo con radicales polares, método para su obtención y uso de los mismos.

Country Status (30)

Country Link
EP (1) EP1307237B9 (es)
JP (1) JP2004506026A (es)
KR (2) KR20080027397A (es)
CN (1) CN1468113A (es)
AR (1) AR035342A1 (es)
AT (1) ATE359093T1 (es)
AU (2) AU7977701A (es)
BG (1) BG107541A (es)
BR (1) BR0113187A (es)
CA (1) CA2419259A1 (es)
CZ (1) CZ2003341A3 (es)
DE (2) DE10040858C2 (es)
DK (1) DK1307237T3 (es)
EE (1) EE200300060A (es)
ES (1) ES2284671T3 (es)
HR (1) HRP20030171A2 (es)
HU (1) HUP0300769A3 (es)
IL (1) IL154329A0 (es)
MX (1) MXPA03001286A (es)
NO (1) NO20030649L (es)
NZ (1) NZ524080A (es)
PL (1) PL365367A1 (es)
PT (1) PT1307237E (es)
RU (1) RU2289579C2 (es)
SK (1) SK286239B6 (es)
UA (1) UA74004C2 (es)
UY (1) UY26873A1 (es)
WO (1) WO2002013875A2 (es)
YU (1) YU10503A (es)
ZA (1) ZA200301947B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7344704B2 (en) 2002-07-10 2008-03-18 Schering Ag Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of intravascular thrombi
DE10231799B4 (de) * 2002-07-10 2006-10-05 Schering Ag Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Intravasalen Thromben
JP2009509915A (ja) * 2005-07-15 2009-03-12 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト ペルフルオロアルキル含有錯体、ならびにｎｍｒ、ｘ線および放射線診断、さらに放射線治療のための造影剤としてのその使用法
DE102005033902B3 (de) * 2005-07-15 2007-04-05 Schering Ag Perfluoralkylhaltige Komplexe, Verfahren zu deren Herstellung, sowie deren Verwendung und diese enthaltende pharmazeutische Mittel
DE102005033903B4 (de) * 2005-07-15 2007-08-09 Bayer Schering Pharma Ag Perfluoralkylhaltige Komplexe, Verfahren zu deren Herstellung, sowie deren Verwendung und diese enthaltende pharmazeutische Mittel
DE102006049821A1 (de) 2006-10-18 2008-04-24 Bayer Schering Pharma Aktiengesellschaft Metallchelate mit perfluoriertem PEG-Rest, Verfahren zu deren Herstellung, sowie deren Verwendung
DE102007015598A1 (de) * 2007-03-29 2008-10-02 Heinrich-Heine-Universität Düsseldorf Verwendung von fluorhaltigen Verbindungen zu Diagnosezwecken mit Hilfe bildgebender Verfahren
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
CA3044877A1 (en) 2016-11-28 2018-05-31 Bayer Pharma Aktiengesellschaft High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging
RU2681319C1 (ru) * 2017-10-27 2019-03-06 Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский экономический университет имени Г.В. Плеханова" (ФГБОУ ВО "РЭУ им. Г.В. Плеханова") Ультраволокнистый биополимерный материал с бактерицидным эффектом
EP3883613A1 (en) 2018-11-23 2021-09-29 Bayer Aktiengesellschaft Formulation of contrast media and process of preparation thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4317588C2 (de) * 1993-05-24 1998-04-16 Schering Ag Fluorhaltige makrocyclische Metallkomplexe, Verfahren zu ihrer Herstellung, sowie ihre Verwendung
DE19603033A1 (de) * 1996-01-19 1997-07-24 Schering Ag Perfluoralkylhaltige Metallkomplexe, Verfahren zu deren Herstellung und ihre Verwendung in der NMR-Diagnostik
DE19608278A1 (de) * 1996-02-23 1997-08-28 Schering Ag Pharmazeutische Mittel enthaltend perfluoralkylhaltige Metallkomplexe, und ihre Verwendung in der Tumortherapie und interventioniellen Radiologie
DE19729013A1 (de) * 1997-07-03 1999-02-04 Schering Ag Oligomere, perfluoralkylhaltige Verbindungen, Verfahren zu deren Herstellung und ihre Verwendung in der NMR-Diagnostik
DE19744004C1 (de) * 1997-09-26 1999-07-22 Schering Ag Lipophile Metall-Komplexe für Nekrose und Infarkt-Imaging

Also Published As

Publication number Publication date
WO2002013875A3 (de) 2002-08-22
UA74004C2 (en) 2005-10-17
SK1552003A3 (en) 2003-09-11
AR035342A1 (es) 2004-05-12
YU10503A (sh) 2006-08-17
EP1307237B1 (de) 2007-04-11
MXPA03001286A (es) 2004-04-20
DE10040858C2 (de) 2003-12-18
CN1468113A (zh) 2004-01-14
JP2004506026A (ja) 2004-02-26
PL365367A1 (en) 2004-12-27
HUP0300769A3 (en) 2009-03-02
HRP20030171A2 (en) 2004-06-30
WO2002013875A2 (de) 2002-02-21
ES2284671T3 (es) 2007-11-16
ATE359093T1 (de) 2007-05-15
SK286239B6 (sk) 2008-06-06
NO20030649D0 (no) 2003-02-10
DE10040858A1 (de) 2002-03-28
BG107541A (bg) 2004-01-30
IL154329A0 (en) 2003-09-17
HUP0300769A2 (hu) 2003-09-29
PT1307237E (pt) 2007-07-02
CZ2003341A3 (cs) 2003-05-14
ZA200301947B (en) 2004-06-25
KR20080027397A (ko) 2008-03-26
AU7977701A (en) 2002-02-25
DK1307237T3 (da) 2007-07-02
RU2289579C2 (ru) 2006-12-20
AU2001279777B2 (en) 2006-08-31
DE50112336D1 (de) 2007-05-24
EP1307237B9 (de) 2008-01-09
EE200300060A (et) 2004-12-15
CA2419259A1 (en) 2002-02-21
NO20030649L (no) 2003-04-11
KR20030022381A (ko) 2003-03-15
BR0113187A (pt) 2003-07-01
EP1307237A2 (de) 2003-05-07
NZ524080A (en) 2005-10-28

Similar Documents

Publication Publication Date Title
UY26873A1 (es) Complejos que contienen perfluoralquilo con radicales polares, método para su obtención y uso de los mismos.
CL2023002956A1 (es) Inhibidor de la proteasa 1 específica de ubiquitina (usp1)
CR11036A (es) Derivados y composiciones de isoindol 4' -o- sustituidos, composiciones que las comprenden y metodos de uso de los mismos
ECSP21052184A (es) Inhibidores de apol1 y sus métodos de uso
CO6321248A2 (es) Derivados de triazol utiles para el tratamiento de enfermedades
UY28342A1 (es) Nuevos compuestos
SV2007002397A (es) Aminopiridinas como inhibidores de b-secretasa ref. am101663
SV2006002208A (es) Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteina quinasa ref. pc32546a
CL2012002526A1 (es) Uso de compuestos inhibidores de dpp iv de formula (i) o (ii) o una de sus sales, para el tratamiento de falla cardiaca.
CO6300939A2 (es) Compuestos novedosos que son inhibidores de erk referencia a una solicitud relacionada
UY30846A1 (es) Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
CR8360A (es) 1,3 dimetilbutilcarboxanilidas
CO5690610A2 (es) Fagos aislados y su uso como desinfectante en alimento o para la higienizacion del ambiente industrial
CL2009001686A1 (es) Procedimiento de preparacion de agomelatina; y los compuestos intermediarios considerados.
MX2020012344A (es) Butirato alimenticio.
CR8135A (es) Triazolopirimidinas
UY29434A1 (es) Derivados de tetrahidronaftalina, procedimientos para su preparación y su uso como inhibidores de la inflamacinn
ES2529434T3 (es) Método para tratar neoplasias hematopoyéticas
SV2006002220A (es) Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparacion y su uso como antiinflamatorios ref. p-sv-78.836/cd
ECSP088512A (es) Uso de piraclostrobina como asegurador para triticonazol para combatir hongos nocivos
CR9645A (es) Complejos con contenido de perfluoroalquilo, procedimientos para su preparacion asi como su uso
CR8443A (es) Pirazolopirimidinas
BRPI0411837A (pt) pirazolopirimidinas
IL184292A0 (en) Treatment of drug-resistant proliferative disorders
GT200900087A (es) Quelatos metalicos con radical peg perflurado metodo para su preparacion y su uso.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20141001